# A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2021 · $154,440

## Abstract

ABSTRACT
This administrative supplement application is intended to support the timely and full completion of the
originally proposed study and to offset delays caused by the COVID-19 Pandemic. As detailed in this
supplement, we have dealt with a host of COVID-19 related delays, while also maintaining the laboratory
open and conducting ongoing recruitment to the maximum degree allowed by the UCLA COVID-19
Response and Recovery Task Force. In this supplement application we provide details that justify the
request for additional resources to effectively complete the original project and to mitigate COVID-19
delays in recruitment. We note that a systematic process of evaluating the forced closures (either by the
University or as a result of staff contracting and managing COVID-19 infection) and their impact on
recruitment was undertaken in order to reach a sensible and data-informed budgetary request. Despite
the challenges of the COVID-19 pandemic our team has been resilient and hard-working. We have
maintained recruitment efforts to the best of our ability and completed 24 randomizations during a full year
of COVID-19 disruption. This is a testament to our commitment to this research. Notably, we have kept
the protocol integrity and have only conducted a minimum of telephone and zoom-based follow-up
sessions. This allowed us to stay consistent with regard to the proposed protocol, provide careful
medication management, verify medication compliance, and obtain all necessary clinical safety labs at the
beginning and the end of study participation. This administrative supplement application will support the
timely and full completion of the originally proposed study.

## Key facts

- **NIH application ID:** 10387454
- **Project number:** 3R01AA026190-04S1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** LARA A. RAY
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $154,440
- **Award type:** 3
- **Project period:** 2021-04-08 → 2023-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10387454

## Citation

> US National Institutes of Health, RePORTER application 10387454, A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder (3R01AA026190-04S1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10387454. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*